RESUMO
CONTEXT: Lipodystrophy syndromes are rare disorders of deficient adipose tissue, low leptin, and severe metabolic disease, affecting all adipose depots (generalized lipodystrophy, GLD) or only some (partial lipodystrophy, PLD). Left ventricular (LV) hypertrophy is common (especially in GLD); mechanisms may include hyperglycemia, dyslipidemia, or hyperinsulinemia. OBJECTIVE: Determine effects of recombinant leptin (metreleptin) on cardiac structure and function in lipodystrophy. METHODS: Open-label treatment study of 38 subjects (18 GLD, 20 PLD) at the National Institutes of Health before and after 1 (Nâ =â 27), and 3 to 5 years (Nâ =â 23) of metreleptin. Outcomes were echocardiograms, blood pressure (BP), triglycerides, A1c, and homeostasis model assessment of insulin resistance. RESULTS: In GLD, metreleptin lowered triglycerides (median [interquartile range] 740 [403-1239], 138 [88-196], 211 [136-558] mg/dL at baseline, 1 year, 3-5 years, Pâ <â .0001), A1c (9.5â ±â 3.0, 6.5â ±â 1.6, 6.5â ±â 1.9%, Pâ <â .001), and HOMA-IR (34.1 [15.2-43.5], 8.7 [2.4-16.0], 8.9 [2.1-16.4], Pâ <â .001). Only HOMA-IR improved in PLD (Pâ <â .01). Systolic BP decreased in GLD but not PLD. Metreleptin improved cardiac parameters in patients with GLD, including reduced posterior wall thickness (9.8â ±â 1.7, 9.1â ±â 1.3, 8.3â ±â 1.7 mm, Pâ <â .01), and LV mass (140.7â ±â 45.9, 128.7â ±â 37.9, 110.9â ±â 29.1 g, Pâ <â .01), and increased septal e' velocity (8.6â ±â 1.7, 10.0â ±â 2.1, 10.7â ±â 2.4 cm/s, Pâ <â .01). Changes remained significant after adjustment for BP. In GLD, multivariate models suggested that reduced posterior wall thickness and LV mass index correlated with reduced triglycerides and increased septal e' velocity correlated with reduced A1c. No changes in echocardiographic parameters were seen in PLD. CONCLUSION: Metreleptin attenuated cardiac hypertrophy and improved septal e' velocity in GLD, which may be mediated by reduced lipotoxicity and glucose toxicity. The applicability of these findings to leptin-sufficient populations remains to be determined.
Assuntos
Cardiomegalia/prevenção & controle , Hipertrofia Ventricular Esquerda/prevenção & controle , Leptina/análogos & derivados , Lipodistrofia/complicações , Lipodistrofia/tratamento farmacológico , Adolescente , Adulto , Pressão Sanguínea , Cardiomegalia/etiologia , Ecocardiografia , Feminino , Hemoglobinas Glicadas/análise , Humanos , Hipertrofia Ventricular Esquerda/patologia , Hipertrofia Ventricular Esquerda/fisiopatologia , Resistência à Insulina , Leptina/uso terapêutico , Lipodistrofia/patologia , Lipodistrofia Generalizada Congênita/complicações , Lipodistrofia Generalizada Congênita/dietoterapia , Masculino , Pessoa de Meia-Idade , National Institutes of Health (U.S.) , Estudos Prospectivos , Triglicerídeos/sangue , Estados Unidos , Septo Interventricular/patologia , Septo Interventricular/fisiopatologia , Adulto JovemRESUMO
CONTEXT: Insulin and leptin may increase growth and proliferation of thyroid cells, underlying an association between type 2 diabetes and papillary thyroid cancer (PTC). Patients with extreme insulin resistance due to lipodystrophy or insulin receptor mutations (INSR) are treated with high-dose insulin and recombinant leptin (metreleptin), which may increase the risk of thyroid neoplasia. OBJECTIVE: The aim of this study was to analyze thyroid structural abnormalities in patients with lipodystrophy and INSR mutations and to assess whether insulin, IGF-1, and metreleptin therapy contribute to the thyroid growth and neoplasia in this population. DESIGN: Thyroid ultrasound characteristics were analyzed in 81 patients with lipodystrophy and 11 with INSR (5 homozygous; 6 heterozygous). Sixty patients were taking metreleptin. RESULTS: The prevalence of thyroid nodules in children with extreme insulin resistance (5 of 30, 16.7%) was significantly higher than published prevalence for children (64 of 3202; 2%), with no difference between lipodystrophy and INSR. Body surface area-adjusted thyroid volume was larger in INSR homozygotes vs heterozygotes or lipodystrophy (10.4 ± 5.1, 3.9 ± 1.5, and 6.2 ± 3.4 cm2, respectively. Three patients with lipodystrophy and one INSR heterozygote had PTC. There were no differences in thyroid ultrasound features in patients treated vs not treated with metreleptin. CONCLUSION: Children with extreme insulin resistance had a high prevalence of thyroid nodules, which were not associated with metreleptin treatment. Patients with homozygous INSR mutation had thyromegaly, which may be a novel phenotypic feature of this disease. Further studies are needed to determine the etiology of thyroid abnormalities in patients with extreme insulin resistance.